|本期目录/Table of Contents|

[1]匡衡,蔡欣,汪茂荣.鼠疫疫苗研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(03):307-310.[doi:10.3969/j.issn.1672-271X.2021.03.018]
　KUANG Heng,CAI Xin,WANG Mao-rong.Progress in plague vaccine research[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(03):307-310.[doi:10.3969/j.issn.1672-271X.2021.03.018]
点击复制

鼠疫疫苗研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第23卷
期数:
2021年03期
页码:
307-310
栏目:
综述
出版日期:
2021-06-20

文章信息/Info

Title:
Progress in plague vaccine research
作者:
匡衡; 蔡欣; 汪茂荣
作者单位：210002南京,安徽医科大学八一临床学院 (匡衡、蔡欣)；210002 南京，东部战区总医院秦淮医疗区肝病科（汪茂荣）
Author(s):
KUANG Heng;  CAI Xin ; WANG Mao-rong
(1.Anhui Medical University Affiliated with Bayi Clinical College，Nanjing 210002, Jiangsu, China;2. Institute of Liver Disease, General Hospital of Eastern Theater Command,PLA, Nanjing 210002, Jiangsu, China)
关键词:
鼠疫; 疫苗; 研究进展
Keywords:
plague;  vaccines;  advances in research
分类号:
R516.8
DOI:
10.3969/j.issn.1672-271X.2021.03.018
文献标志码:
A
摘要:
鼠疫主要依赖抗生素治疗，近年来随着耐药鼠疫杆菌的发现及流行，鼠疫疫苗的应用逐渐增多。目前国内使用的鼠疫疫苗主要为减毒活疫苗，而亚单位疫苗、结合疫苗和DNA疫苗仍在研发中，文章主要就近年来鼠疫疫苗的研究方向，研究突破和对未来鼠疫疫苗应用的展望进行综述。
Abstract:
Plague is mainly handled by antibiotics. With the discovery and prevalence of drug-resistant Yersinia pestis in recent years, the application of plague vaccine is increasing gradually.Presently, the plague vaccine used in China is mainly live attenuated vaccine, while the subunit vaccine, conjugate vaccine and DNA vaccine are still under development. In this paper, the research direction of plague vaccine in recent years, the research breakthrough and the prospect of future application of plague vaccine is summarized.

参考文献/References:

[1]李书宝，戴绘. 世界鼠疫疫情态势及研究进展[J]. 中国地方病防治杂志, 2000,15(1): 21-26.
[2]Steensma DP，Kyle RA. Alexandre Yersin: Discoverer of the Plague Bacillus[J]. Mayo Clin Proc, 2020, 95(1): 7-8.
[3]Cui Y, Yang X, Xiao X, et al. Genetic variations of live attenuated plague vaccine strains (Yersinia pestis EV76 lineage) during laboratory passages in different countries[J]. Infect Genet Evol, 2014, 26: 172-179.
[4]Sun W, Curtiss R. Rational considerations about development of live attenuated Yersinia pestis vaccines[J]. Curr Pharm Biotechnol, 2013,14(10): 878.
[5]Sun W. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague[J]. Vaccine, 2011, 29(16): 2986-2998.
[6]Wang X, Singh AK, Sun W. Protection and Safety Evaluation of Live Constructions Derived from the Pgm-and pPCP1-Yersinia pestis Strain[J]. Vaccines, 2020, 8(1): 95.
[7]Depaolo RW, Tang F, Kim I, et al. Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis[J]. Cell Host Microbe, 2008,4(4): 350-361.
[8]Sing A, Reithmeier-Rost D, Granfors K, et al. A Hypervariable N-Terminal Region of Yersinia LcrV Determines Toll-like Receptor 2-Mediated IL-10 Induction and Mouse Virulence[J]. Proc Natl Acad Sci USA, 2005, 102(44):16049-16054.
[9]Branger CG, Torres-Escobar A, Sun W, et al. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonellaenterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica[J]. Vaccine, 2009, 27(39): 5363-5370.
[10]Sanapala S, Rahav H, Patel H,et al. Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague[J]. Vaccine, 2016, 34(21): 2410-2416.
[11]van Lier CJ, Tiner BL, Chauhan S, et al. Further characterization of a highly attenuated Yersinia pestis CO92 mutant deleted for the genes encoding Braun lipoprotein and plasminogen activator protease in murine alveolar and primary human macrophages[J]. Microb Pathog, 2015, 80: 27-38.
[12]Tiner BL, Sha J, Ponnusamy D, et al. Intramuscular Immunization of Mice with a Live-Attenuated Triple Mutant of Yersinia pestis CO92 Induces Robust Humoral and Cell-Mediated Immunity To Completely Protect Animals against Pneumonic Plague[J]. Clin Vaccine Immunol, 2015, 22(12): 1255-1268.
[13]Leary SE, Griffin KF, Garmory HS, et al. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague[J]. Microb Pathog, 1997, 23(3): 167-179.
[14]Bowen W, Batra L, Pulsifer AR, et al. Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague[J]. Vaccine, 2019, 37(38): 5708-5716.
[15]Dinc G, Pennington JM, Yolcu ES, et al. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant[J]. Vaccine, 2014, 32(39): 5035-5040.
[16]Gregg KA, Harberts E, Gardner FM, et al. A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model[J]. Vaccine, 2018, 36(28): 4023-4031.
[17]Wang W, Qi ZZ, Zhang QW, et al. Different strategies for preparation of non-tagged rV270 protein and its efficacy against Yersinia pestis challenge[J]. Biomed Environ Sci, 2010, 23(5): 333-340.
[18]Wang Z, Zhou L, Qi Z, et al. Long-Term Observation of Subunit Vaccine F1-rV270 against Yersinia pestis in Mice[J]. Clin Vaccine Immunol, 2010, 17(1): 199-201.
[19]Bhattacharya D, Mecsas J, Hu LT. Development of a vaccinia virus based reservoir-targeted vaccine against Yersinia pestis[J]. Vaccine, 2010, 28(48): 7683-7689.
[20]Embry A, Meng X, Cantwell A, et al. Enhancement of immune response to an antigen delivered by vaccinia virus by displaying the antigen on the surface of intracellular mature virion[J]. Vaccine, 2011, 29(33): 5331-5339.
[21]范凌云,谢庆军. 腺病毒载体的研究进展[J]. 中国生物制品学杂志, 2008, 21(2): 153-157.
[22]Sofer-Podesta C, Ang J, Hackett NR, et al. Adenovirus-Mediated Delivery of an Anti-V Antigen Monoclonal Antibody Protects Mice against a Lethal Yersinia pestis Challenge[J]. Infect Immun, 2009, 77(4): 1561-1568.
[23]Sha J, Kirtley ML, Klages C, et al. A Replication-Defective Human Type 5 Adenovirus-Based Trivalent Vaccine Confers Complete Protection against Plague in Mice and Nonhuman Primates[J]. Clin Vaccine Immunol, 2016, 23(7): 586-600.
[24]李学荣,余新炳. 核酸疫苗及其免疫机制研究[J]. 中国人兽共患病杂志, 2000,6: 82-86.
[25]Yamanaka H, Hoyt T, Yang X, et al. A parenteral DNA vaccine protects against pneumonic plague[J]. Vaccine, 2010, 28(18): 3219-3230.
[26]Albrecht MT, Livingston BD, Pesce JT, et al. Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague[J]. Vaccine, 2012, 30(32): 4872-4883.
[27]Wang S, Goguen JD, Li F, et al. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge[J]. Vaccine, 2011, 29(39): 6802-6809.

相似文献/References:

[1]杨辛怡综述,季国忠审校.幽门螺杆菌感染的治疗方案[J].医学研究与战创伤救治(原医学研究生学报),2017,19(03):280.[doi:10.3969/j.issn.1672-271X.2017.03.015]
[2]陈春霞,胡素琴,王桂玲.军队医院应急接种重组新型冠状病毒疫苗的流程建立与管理实践[J].医学研究与战创伤救治(原医学研究生学报),2021,23(6):660.[doi:10.3969/j.issn.1672-271X.2021.06.023]
[3]王晴,陈雁,王清,等.常态化疫情防控下三级医疗机构新冠病毒疫苗临时接种点管理实践[J].医学研究与战创伤救治(原医学研究生学报),2022,24(1):93.[doi:10.3969/j.issn.1672-271X.2022.01.022]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2021-06-17